$13.15▴ 3.95%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-1.10cash per $1 profit
Weak
Much of its reported profit is not backed by operating cash.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
Not enough data yet
Not enough revenue history to measure growth.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
Omeros Corporation turns -110¢ of every reported profit-dollar into real cash. Much of its reported profit is not backed by operating cash.
Key numbers
Valuation
EPS (TTM)$1.14
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin871.0%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$9.89M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days4 articles
0 bullish1 neutral3 bearish
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Omeros Corporation - OMER
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Omeros Corporation - OMER
Omeros Corporation Investigated by the Portnoy Law Firm
Heartflow vs. Omeros: Which Healthcare Innovator Stock Is a Better Buy in 2026?
Intellia Therapeutics vs. Omeros: Which Emerging Biotech Stock Is a Better Buy in 2026?
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.